GRUENDEL Rechtsanwälte advises Evonik and bm|t beteiligungsmanagement thüringen GmbH on Series A financing for JeNaCell GmbH
Jena-based JeNaCell GmbH, a spin-off from Friedrich-Schiller University in Jena, completed a Series A financing round with Evonik, one of the world’s leading specialty chemical companies, and bm|t beteiligungsmanagement thüringen GmbH as well as Sparkasse Jena savings bank. Existing investors HTGF and STIFT also participated in the financing round.
JeNaCell is a specialist in biotechnology-derived nanocellulose and uses a manufacturing process unique in this field. The capital obtained will be used to further expand production capacity at the Jena facility and step up marketing and sales activities.
In pursuing its venture capital activities, Evonik aims to invest a total of €100 million in promising start-ups with innovative technologies and in leading specialised venture capital funds. The regional focus is on Europe, the US and Asia. Currently, Evonik holds equity interests in six start-ups and three funds.
Advisors of Evonik and bm|t:
- GRUENDEL Rechtsanwälte: Dr. Steffen Fritzsche (Corporate, Lead), Florian Helbig (Commercial) (beide Leipzig), Dr. Mathis Hoffmann (IP) (Jena)